Agilent Technologies Inc (A)vsGRAIL, LLC (GRAL)
A
Agilent Technologies Inc
$126.49
-2.12%
HEALTHCARE · Cap: $36.67B
GRAL
GRAIL, LLC
$62.10
-9.87%
HEALTHCARE · Cap: $2.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Agilent Technologies Inc generates 4532% more annual revenue ($7.23B vs $156.12M). A leads profitability with a 19.6% profit margin vs -253.2%. A earns a higher WallStSmart Score of 71/100 (B).
A
Strong Buy71
out of 100
Grade: B
GRAL
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.0%
Fair Value
$74.53
Current Price
$126.49
$51.96 premium
Intrinsic value data unavailable for GRAL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 60.0% YoY
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 28.1% year-over-year
Areas to Watch
Moderate valuation
Grey zone — moderate risk
Weak financial health signals
0.0% earnings growth
ROE of -15.8% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : A
The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : GRAL
The strongest argument for GRAL centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 28.1% demonstrates continued momentum.
Bear Case : A
The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
A profiles as a mature stock while GRAL is a growth play — different risk/reward profiles.
GRAL is growing revenue faster at 28.1% — sustainability is the question.
A generates stronger free cash flow (184M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
A scores higher overall (71/100 vs 35/100), backed by strong 19.6% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agilent Technologies Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a pioneering biotechnology company at the forefront of cancer diagnostics, focusing on innovative blood tests for multi-cancer early detection (MCED) that utilize its proprietary genomic technologies. Committed to advancing precision medicine, GRAIL aims to transform the oncology landscape by providing individuals with essential insights for proactive health management and improving overall patient outcomes. Its groundbreaking efforts address significant unmet needs in cancer screening and diagnostics, positioning the company as a key player in the rapidly evolving field of cancer care.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?